Clinical trial · Observational
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
NCT06958107CI-TRIAL-00119117recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ALT or WDLS | Other | — | UNRESOLVED |
| Metastatic and Un-resectable | Other | — | UNRESOLVED |
| No evidence of disease, under surveillance | Other | — | UNRESOLVED |
| Non-Metastatic and Resectable | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Non-Metastatic and Resectable
- description
- Cohort A1: Non-metastatic/ Resectable (with planned or you are undergoing therapy)- your cancer has not spread, may be able to remove it with operation
- interventionNames
- Other: Non-Metastatic and Resectable
- label
- Metastatic and Un-resectable
- description
- Cohort A2: Metastatic/ Unresectable (with planned or you are undergoing therapy)- your cancer has spread, not able to operate at this time to take out all the cancer
- interventionNames
- Other: Metastatic and Un-resectable
- label
- No evidence of disease, under surveillance
- description
- Cohort B: No evidence of disease/ surveillance (you have completed initial therapy)- currently there is no evidence of your cancer/disease and you are under surveillance, meaning your physician is checking your medical situation at intervals or occasionally for any sign of changes
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:
1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.
2. All ages allowed
3. Suspected or confirmed disease (must meet one of the criteria below):
1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)
OR
2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery
OR
3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:
* Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy
* Metastatic or unresectable sarcoma, with planned or currently receiving therapy
* Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy
Exclusion Criteria:
* noneReferences
Publications (0)
Data not yet available
No reference posted for this study.